|
CCRN4L expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.93599955248203E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.0590998057487E-10 |
| Normal-vs-Stage2 |
1.77800000278339E-08 |
| Normal-vs-Stage3 |
4.74049999255044E-09 |
| Normal-vs-Stage4 |
2.29590013667291E-10 |
| Stage1-vs-Stage2 |
4.008600E-01 |
| Stage1-vs-Stage3 |
7.252000E-01 |
| Stage1-vs-Stage4 |
3.564600E-01 |
| Stage2-vs-Stage3 |
7.491000E-01 |
| Stage2-vs-Stage4 |
2.092200E-01 |
| Stage3-vs-Stage4 |
3.449400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.79559980404565E-10 |
| Normal-vs-AfricanAmerican |
1.515360E-03 |
| Normal-vs-Asian |
1.61490043559809E-10 |
| Caucasian-vs-AfricanAmerican |
1.809970E-01 |
| Caucasian-vs-Asian |
1.859780E-01 |
| AfricanAmerican-vs-Asian |
7.564200E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.26910054582186E-10 |
| Normal-vs-Female |
1.31459998442551E-09 |
| Male-vs-Female |
2.622800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.24959989209617E-10 |
| Normal-vs-Age(41-60Yrs) |
1.00830011007247E-10 |
| Normal-vs-Age(61-80Yrs) |
2.80719999468104E-08 |
| Normal-vs-Age(81-100Yrs) |
3.396200E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.364030E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.235000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.146000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.556100E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.465200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.009400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.568600E-01 |
| Classical-VS-Follicular |
4.122600E-01 |
| Classical-VS-Other |
8.698400E-03 |
| Classical-VS-Normal |
1.77720005378745E-09 |
| Tall-VS-Follicular |
2.848000E-01 |
| Tall-VS-Other |
1.862170E-01 |
| Tall-VS-Normal |
4.91590000040176E-07 |
| Follicular-VS-Other |
3.463700E-03 |
| Follicular-VS-Normal |
1.43070000291345E-08 |
| Other-VS-Normal |
1.26719967852296E-10 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.66260055407031E-10 |
| Normal-vs-N1 |
2.08539852053491E-11 |
| N0-vs-N1 |
2.471700E-02 |
|
|
